01—Abstract
Summary
Summary of the 8-K filed October 5, 2026. Cited figures are marked; the original filing is the authoritative source.
AbbVie Inc. (ABBV) has filed an 8-K report to provide an update on its financial outlook, specifically addressing the impact of acquired in-process research and development (IPR&D) and milestones expenses for the third quarter of 2026.
The company expects these costs to be approximately $216 milliona pre-tax, resulting in an unfavorable impact of $0.11 per share on both GAAP and adjusted non-GAAP diluted earnings per share for the quarter. These figures are preliminary and subject to final financial closing procedures. The company has reiterated its full-year 2026 adjusted diluted earnings per share guidance range of $13.76 - $13.96, which now incorporates the anticipated impact of the third-quarter IPR&D and milestones expenses.
The third-quarter 2026 adjusted diluted earnings per share guidance has been updated to a range of $3.73b - $3.77, reflecting these expenses. AbbVie emphasizes that acquired IPR&D and milestone expenses are difficult to forecast due to the inherent uncertainty in the timing and occurrence of such transactions, and their previously announced guidance excluded such expenses beyond the second quarter of 2026.
02—Key points
Key Highlights
- AbbVie anticipates a $216 million pre-tax impact from acquired IPR&D and milestones expenses in Q3 2026.
- These expenses are expected to reduce Q3 2026 GAAP and adjusted diluted EPS by $0.11 each.
- Full-year 2026 adjusted diluted EPS guidance is reaffirmed at $13.76 - $13.96, now including Q3 IPR&D/milestones expenses.
- Q3 2026 adjusted diluted EPS guidance is updated to a range of $3.73 - $3.77, incorporating these expenses.
- The company notes the inherent unpredictability of acquired IPR&D and milestone expenses, which are not typically forecasted.
- This information is presented as preliminary and subject to final financial closing procedures.
- The report includes forward-looking statements, cautioning investors about risks and uncertainties that could affect actual results.
03—Questions
Frequently Asked Questions
What are acquired IPR&D and milestones expenses?
Acquired IPR&D and milestones expenses typically arise from collaborations, licensing agreements, or other asset acquisitions where AbbVie secures rights to research and development projects or makes payments upon the achievement of certain developmental milestones. These costs are associated with the acquisition of intangible assets related to research and development activities that have not yet reached technological feasibility.
How does this impact AbbVie's profitability for Q3 2026?
For the third quarter of 2026, these expenses are projected to reduce both GAAP and adjusted diluted earnings per share by $0.11 each. The preliminary adjusted diluted EPS guidance for the quarter, reflecting this impact, is now between $3.73 and $3.77.
Has AbbVie's full-year 2026 earnings guidance changed?
AbbVie has reaffirmed its full-year 2026 adjusted diluted earnings per share guidance range of $13.76 to $13.96. This guidance now includes the estimated impact of the acquired IPR&D and milestones expenses incurred during the third quarter.
Why does AbbVie not typically forecast these expenses?
AbbVie does not forecast acquired IPR&D and milestones expenses because the occurrence and timing of these transactions are inherently uncertain. They depend on external factors such as the successful execution of licensing agreements and the progression of research and development projects, making them difficult to predict accurately.
04—Continue